Editorial Advisory Board members bring research findings to ARVO

EAB members will present on topics in retina, glaucoma, autoimmune disease management and more Image credit: ©pabrady63 – stock.adobe.com

The 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting is taking place in Salt Lake City, Utah, from 4-8 May, 2025. Presenters and researchers from around the globe are onsite at the ARVO meeting to share innovations in eye care, new technologies and data from clinical trials.

As the presenters prepare for their poster sessions and podium speeches, we are highlighting some of the scheduled sessions that will feature members of the Editorial Advisory Boards of Ophthalmology Times, Modern Retina, and Ophthalmology Times Europe.

Charles Wykoff, MD, PhD

• Poster B0048: Safety, tolerability, and properties of novel C3 inhibitor BI-C in patients with geographic atrophy
  Sunday, May 4, 2025, 1:00-2:45 PM MT

Rishi P. Singh, MD

• Poster: B0088: Two-year real-world clinical outcomes in patients with diabetic macular oedema treated with faricimab in the US: The FARETINA-DME study
  Monday, May 5, 2025. 3:00-4:45 PM MT
  Summary: The FARETINA-DME study evaluates real-world effectiveness, safety, and durability of faricimab for diabetic macular oedema treatment. Results show improved vision and reduced swelling in patients with diabetic macular oedema treated with faricimab.

Anat Loewenstein, MD

• Poster B0300: Interim results of the DME AWARE Delphi Study on unmet needs in diabetic macular oedema patient management
  Monday, May 5, 2025, 3:00-4:45 PM MT
  Summary: DME AWARE Delphi Study identifies unmet needs in diabetic macular oedema patient management. Experts reached consensus on early intervention definitions, treatment considerations, and switch criteria. Novel therapies and mechanisms are needed to address disease progression.

Judy E. Kim, MD, FARVO, FASRS

• Presentation: Lower socioeconomic status is associated with increased bevacizumab use among patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular oedema
• Wednesday, May 7, 2025, 11:45 AM -12:00 PM MT
• Summary: Lower socioeconomic status is linked to increased use of bevacizumab among patients with diabetic macular oedema.

Prof Jean-François Korobelnik

• Presentation: A PULSAR phase 3 trial post-hoc analysis: Evaluating the timing and magnitude of control of disease activity with aflibercept 8 mg and faricimab, applying similar disease activity criteria across different pivotal Phase 3 trials for neovascular age-related macular degeneration
• Sunday, May 4, 2025, 1:15-1:30 PM MT

Tunde Peto, MD, PhD, FRCOphth

• Poster: B0075: Effectiveness and safety of faricimab in eyes with diabetic macular oedema in the United Kingdom: 1-year results from the FARWIDE-DME study
• Monday, May 5, 2025, 3:00-4:45 PM MT

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

• Poster A0412: Association of ocular inflammation with anti-adalimumab antibodies in the management of autoimmune diseases
• May 4, 202,5 Sunday, 8:00-9:45 AM MT
• Summary: Anti-adalimumab antibodies associated with ocular inflammation in autoimmune disease management.

David A. Eichenbaum, MD, FASRS

• Poster: A0382: Real-world treatment patterns in patients with macular oedema (ME) due to noninfectious uveitis (NIU) in the United States
• May 4, 2025 1:00-2:45 PM MT
• Summary: Real-world treatment patterns in US patients with macular oedema due to noninfectious uveitis were analysed using a large database. Locally administered corticosteroids remain the standard of care but are associated with side effects. An unmet need exists for effective and safe nonsteroid alternatives.

Robert N. Weinreb, MD

• Minisymposium: Revisiting Clinical Trial Endpoints in Glaucoma
• Tuesday, May 6, 2025, 4:40-4:54 PM MT
• Summary: Glaucoma clinical trial endpoints revisited, with focus on visual field and structural parameters as surrogates for neuroprotection.